A system for identifying potential therapeutic targets for chronic pain in multiple sites
By combining the analysis of multiple data types, the intersection of genes and protein targets for chronic pain in multiple areas was determined, which solved the problem of inaccurate identification of therapeutic targets in the prior art and improved the effectiveness of treatment.
Patent Information
- Application Number
- CN202410440719.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-12
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-04-12
AI Technical Summary
The discovery and verification stages of drug targets in the prior art are usually limited to a single data type and analytical methods, resulting in the inability to accurately identify multi-site chronic pain (MCP)-related therapeutic targets, and false positives may occur.
By obtaining gene expression and protein expression data of multiple data types, including GWAS data, GTEx V8 data, deCODE data and NIAGADS data, combined with full transcriptome association analysis, Mendel randomization and Bayesian colocalization analysis, we determined that intervention can be determined The intersection of gene targets and protein targets serves as potential therapeutic targets for MCP.
It has achieved more accurate identification of therapeutic targets related to MCP, and improved the effectiveness and targeting of treatment.
Smart Images

Figure CN118298911B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical science and technology, and in particular to a system for determining potential therapeutic targets for chronic pain in multiple locations. Background Art
[0002] According to the ICD-11 diagnostic criteria and the global burden of disease analysis, multisite chronic pain (MCP) is a disease that affects more than 30% of the world's population. At present, the traditional drug development process usually includes the following main steps: (1) Target discovery and validation: In this stage, researchers search for and validate disease-related biological molecules, such as proteins, genes or cell pathways; (2) Drug screening and optimization: Once potential targets are identified, researchers will conduct high-throughput screening to find compounds with therapeutic potential. Subsequently, these compounds will be optimized to improve their efficacy, selectivity and bioavailability; (3) Preclinical research: Before entering clinical trials, candidate drugs need to be extensively tested in in vitro and in vivo models to evaluate their pharmacokinetics, toxicity and efficacy; (4) Clinical trials: Drug candidates that have undergone preclinical studies will enter the clinical trial stage, which is divided into three stages: Phase I (safety), Phase II (efficacy) and Phase III (large-scale efficacy and safety);
[0003] However, in the existing technology, the discovery and verification stages of drug targets are usually limited to a single data type and analysis method. However, using only one method to judge drug targets may result in false positives, making it impossible to accurately identify therapeutic targets related to MCP. Therefore, how to accurately identify therapeutic targets related to MCP is an urgent problem that needs to be solved. Summary of the invention
[0004] The present invention provides a system for determining potential therapeutic targets for chronic pain in multiple sites. The system determines targets that simultaneously affect gene expression and protein expression of MCP and uses them as potential therapeutic targets for MCP, so as to achieve the purpose of more accurately identifying therapeutic targets related to MCP.
[0005] An embodiment of the present invention provides a system for determining potential therapeutic targets for chronic pain in multiple sites, including: a data acquisition module, an interventionable gene target confirmation module, an interventionable protein target confirmation module, and an MCP potential therapeutic target confirmation module;
[0006] The data acquisition module is used to acquire the first GWAS data, the gene expression data of whole blood and the gene expression data of brain tissue in the GTEx V8 data set, the blood protein expression data in the deCODE data set, and the brain protein expression data in the NIAGADS data set; wherein the first GWAS data is the GWAS data related to MCP;
[0007] The intervenable gene target confirmation module is used to determine a number of intervenable gene targets related to MCP based on the first GWAS data, the gene expression data of the whole blood, and the gene expression data of the brain tissue, and generate an intervenable gene target set;
[0008] The intervenable protein target confirmation module is used to determine a number of intervenable protein targets related to MCP based on the first GWAS data, the blood protein expression data, and the brain protein expression data, and generate an intervenable protein target set;
[0009] The MCP potential therapeutic target confirmation module is used to determine the intersection of the intervenable gene target set and the intervenable protein target set, and use each target in the determined intersection as a potential therapeutic target for MCP.
[0010] Furthermore, the determining of several intervenable gene targets related to MCP based on the first GWAS data, the gene expression data of the whole blood, and the gene expression data of the brain tissue includes:
[0011] Performing whole transcriptome association analysis according to the gene expression data of the whole blood, the gene expression data of the brain tissue, and the corresponding genetic variation data in the first GWAS data to obtain a P value and a first effect value direction of the gene expression data of the whole blood and the gene expression data of the brain tissue;
[0012] Performing FDR correction on the P values of the whole blood gene expression data and the brain tissue gene expression data to obtain first candidate gene expression data whose corrected P value is less than a preset FDR correction threshold;
[0013] Performing SMR&HEIDI analysis on the gene expression data of the whole blood and the gene expression data of the brain tissue to obtain a p-SMR value, a p-HEIDI value and a second effect value direction corresponding to each gene expression data of the whole blood and each gene expression data of the brain tissue;
[0014] Performing FDR correction on the p-SMR value of each gene expression data to obtain candidate gene expression data whose corrected p-SMR value is less than a preset FDR correction threshold, screening out second candidate gene expression data whose p-HEIDI value is greater than a preset value and whose first effect value direction is consistent with the second effect value direction from among the candidate gene expression data whose corrected p-SMR value is less than the preset FDR correction threshold;
[0015] The intersection of the first candidate gene expression data and the second candidate gene expression data is taken, and the gene expression data of the intersection is used as the intervenable gene target associated with MCP.
[0016] Furthermore, the determining of several intervenable protein targets related to MCP based on the first GWAS data, the gene expression data and the brain protein expression data includes:
[0017] Using the blood protein expression data in the deCODE data set and the brain protein expression data in the NIAGADS data set as exposure data for two-sample Mendelian randomization, and using the first GWAS data as result data for two-sample Mendelian randomization, two-sample Mendelian randomization is performed to obtain the third effect value direction and P value corresponding to the blood protein expression data and the brain protein expression data;
[0018] Performing FDR correction on the P values of the blood protein expression data and the brain protein expression data to obtain MR-positive proteins whose corrected P values are less than an FDR correction threshold;
[0019] The MR-positive proteins were subjected to Bayesian co-localization analysis, and the MR-positive proteins with posterior result probabilities greater than preset values were taken as intervenable protein targets associated with MCP.
[0020] Furthermore, the system for determining potential therapeutic targets for chronic pain in multiple sites further includes: a cell analysis module;
[0021] The cell analysis module includes a sequencing data acquisition unit, a key cell type analysis unit, and a cell process analysis unit;
[0022] The sequencing data acquisition unit is used to acquire single-cell RNA sequencing data;
[0023] The key cell type unit is used to analyze and obtain key cell types related to the potential therapeutic target of MCP according to the sc-linker analysis method, the potential therapeutic target of MCP and the single-cell RNA sequencing data;
[0024] The cell process analysis unit is used to analyze and obtain the cell process related to the potential therapeutic target of MCP according to the sc-linker analysis method, the potential therapeutic target of MCP and the single-cell RNA sequencing data.
[0025] Furthermore, the system for determining potential therapeutic targets for chronic pain in multiple sites also includes: an MCP potential therapeutic target action analysis module;
[0026] The MCP potential therapeutic target analysis module is used to obtain the second GWAS data, and obtain a number of associated diseases other than MCP for each intervenable protein target and a corresponding fourth effect value direction based on the number of intervenable protein targets and the second GWAS data;
[0027] According to the third effect value direction and the fourth effect value direction of each of the intervenable protein targets, determining whether the intervenable protein target has side effects on the plurality of related diseases;
[0028] According to the third effect value direction and the fourth effect value direction of each of the intervenable protein targets, it is determined whether the intervenable protein target is an additional indication for the plurality of related diseases.
[0029] Furthermore, the system for determining potential therapeutic targets for chronic pain in multiple sites also includes: a protein network construction and analysis module;
[0030] The protein network construction and analysis module includes a protein network construction unit and a protein network analysis unit;
[0031] The protein network construction unit is used to input the intervenable protein target into a tool for constructing a protein interaction network, so that the tool constructs a network according to the input data;
[0032] The protein network analysis unit is used to analyze the pathways and biological processes involved in the intervenable protein target and the proteins interacting with the intervenable protein target based on the constructed network; wherein the involved pathways and biological processes include: synaptic protein localization, cell-connected protein localization, axonal transport, presynaptic protein localization, axon-dendrite transport and cytoskeleton-dependent intracellular transport.
[0033] The following beneficial effects are achieved by implementing the present invention:
[0034] The present invention provides a system for determining potential therapeutic targets for chronic pain in multiple sites, the system comprising a data acquisition module, an interventionable gene target confirmation module, an interventionable protein target confirmation module and an MCP potential therapeutic target confirmation module; the data acquisition module acquires GWAS data, GTEx After the gene expression data of whole blood and the gene expression data of brain tissue are collected in the V8 data set, the intervenable gene target confirmation module determines several intervenable gene targets related to MCP and generates an intervenable gene target set based on the acquired gene expression data of whole blood and the gene expression data of brain tissue; the intervenable protein target confirmation module determines several intervenable protein targets related to MCP based on the GWAS data and generates an intervenable protein target set; finally, the MCP potential therapeutic target confirmation module determines the intersection of the intervenable gene target set and the intervenable protein target set, and uses each target in the determined intersection as a potential therapeutic target for MCP; thus, this system analyzes the intervenable protein targets related to MCP and several intervenable gene targets related to MCP, and through consistency analysis of gene and protein levels, uses the targets that simultaneously affect the gene expression and protein expression of MCP as potential therapeutic targets for MCP, thereby more accurately identifying therapeutic targets related to MCP to improve the effectiveness and pertinence of MCP treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] In order to more clearly illustrate the technical solution of the present application, the drawings required for use in the implementation manner will be briefly introduced below. Obviously, the drawings described below are only some implementation manners of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0036] Figure 1 It is a schematic diagram of the structure of a system for determining potential therapeutic targets for chronic pain in multiple sites provided by one embodiment of the present invention;
[0037] Figure 2 This is a graph of whole blood results obtained by TWAS analysis provided by an embodiment of the present invention;
[0038] Figure 3 This is a brain tissue result diagram obtained by TWAS analysis provided by an embodiment of the present invention;
[0039] Figure 4 This is a whole blood result diagram obtained by SMR&HEIDI analysis provided by an embodiment of the present invention;
[0040] Figure 5 This is a brain tissue result diagram obtained by SMR&HEIDI analysis provided by an embodiment of the present invention;
[0041] Figure 6This is a cross-result diagram of whole blood obtained by analyzing the TWAS and SMR&HEIDI methods provided in one embodiment of the present invention;
[0042] Figure 7 This is a cross-result diagram of brain tissue obtained by analyzing the TWAS and SMR&HEIDI methods provided in one embodiment of the present invention;
[0043] Figure 8 This is a blood protein result diagram obtained by analyzing the intervenable protein target confirmation module provided by an embodiment of the present invention;
[0044] Fig. 9 This is a brain protein result diagram obtained by analyzing the intervenable protein target confirmation module provided by an embodiment of the present invention;
[0045] Fig.10 It is a schematic diagram of the structure of another system for determining potential therapeutic targets for chronic pain in multiple sites provided by one embodiment of the present invention;
[0046] Fig.11 This is a cell type result diagram obtained by the sc-linker analysis method provided in one embodiment of the present invention;
[0047] Fig.12 This is a result diagram of related cell processes obtained by the sc-linker analysis method provided by one embodiment of the present invention;
[0048] Fig.13 It is a schematic diagram of the structure of another system for determining potential therapeutic targets for chronic pain in multiple sites provided by one embodiment of the present invention;
[0049] Fig.14 It is a schematic diagram of the structure of another system for determining potential therapeutic targets for chronic pain in multiple sites provided by one embodiment of the present invention;
[0050] Fig.15 It is a schematic diagram of the results obtained by analyzing the protein network construction and analysis module provided in one embodiment of the present invention. DETAILED DESCRIPTION
[0051] In order to make the purpose, technical solutions and advantages of this application clearer, the technical solutions in this application will be clearly and completely described below in conjunction with the drawings in the embodiments of this application. Obviously, the described embodiments are part of the embodiments of this application, not all of them. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.
[0052] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by technicians in the technical field to which this application belongs; the terms used herein are only for the purpose of describing specific embodiments and are not intended to limit this application; the terms "including" and "having" in the specification and claims of this application and the above-mentioned figure descriptions and any variations thereof are intended to cover non-exclusive inclusions.
[0053] In the description of the embodiments of the present application, the technical terms "first", "second", etc. are only used to distinguish different objects, and cannot be understood as indicating or implying relative importance or implicitly indicating the number, specific order or primary and secondary relationship of the indicated technical features. In the description of the embodiments of the present application, the meaning of "multiple" is more than two, unless otherwise clearly and specifically defined.
[0054] Reference to "embodiments" herein means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of the phrase in various locations in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.
[0055] In the description of the embodiments of the present application, the term "and / or" is only a description of the association relationship of the associated objects, indicating that there may be three relationships. For example, A and / or B can represent: A exists alone, A and B exist at the same time, and B exists alone. In addition, the character " / " in this article generally indicates that the associated objects before and after are in an "or" relationship.
[0056] In the description of the embodiments of the present application, the term "multiple" refers to more than two (including two). Similarly, "multiple groups" refers to more than two groups (including two groups), and "multiple pieces" refers to more than two pieces (including two pieces).
[0057] In the description of the embodiments of the present application, unless otherwise clearly specified and limited, technical terms such as "installed", "connected", "connected", "fixed" and the like should be understood in a broad sense. For example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection or an indirect connection through an intermediate medium, and it can be the internal connection of two elements or the interaction relationship between two elements. For those of ordinary skill in the art, the specific meanings of the above terms in the embodiments of the present application can be understood according to the specific circumstances.
[0058] See also Figure 1, is a schematic diagram of the structure of a system for determining potential therapeutic targets for chronic pain in multiple sites provided by the present application, comprising: a data acquisition module, an interventionable gene target confirmation module, an interventionable protein target confirmation module, and an MCP potential therapeutic target confirmation module;
[0059] The data acquisition module is used to acquire the first GWAS data, the gene expression data of whole blood and the gene expression data of brain tissue in the GTEx V8 data set, the blood protein expression data in the deCODE data set, and the brain protein expression data in the NIAGADS data set; wherein the first GWAS data is the GWAS data related to MCP;
[0060] The intervenable gene target confirmation module is used to determine a number of intervenable gene targets related to MCP based on the first GWAS data, the gene expression data of the whole blood, and the gene expression data of the brain tissue, and generate an intervenable gene target set;
[0061] The intervenable protein target confirmation module is used to determine a number of intervenable protein targets related to MCP based on the first GWAS data, the blood protein expression data, and the brain protein expression data, and generate an intervenable protein target set;
[0062] The MCP potential therapeutic target confirmation module is used to determine the intersection of the intervenable gene target set and the intervenable protein target set, and use each target in the determined intersection as a potential therapeutic target for MCP;
[0063] In a preferred embodiment, the determining of several intervenable gene targets associated with MCP based on the first GWAS data, the gene expression data of the whole blood, and the gene expression data of the brain tissue includes:
[0064] Performing whole transcriptome association analysis according to the gene expression data of the whole blood, the gene expression data of the brain tissue, and the corresponding genetic variation data in the first GWAS data to obtain a P value and a first effect value direction of the gene expression data of the whole blood and the gene expression data of the brain tissue;
[0065] Performing FDR correction on the P values of the whole blood gene expression data and the brain tissue gene expression data to obtain first candidate gene expression data whose corrected P value is less than a preset FDR correction threshold;
[0066] Performing SMR&HEIDI analysis on the gene expression data of the whole blood and the gene expression data of the brain tissue to obtain a p-SMR value, a p-HEIDI value and a second effect value direction corresponding to each gene expression data of the whole blood and each gene expression data of the brain tissue;
[0067] Performing FDR correction on the p-SMR value of each gene expression data to obtain candidate gene expression data whose corrected p-SMR value is less than a preset FDR correction threshold, screening out second candidate gene expression data whose p-HEIDI value is greater than a preset value and whose first effect value direction is consistent with the second effect value direction from among the candidate gene expression data whose corrected p-SMR value is less than the preset FDR correction threshold;
[0068] Taking the intersection of the first candidate gene expression data and the second candidate gene expression data, and using the gene expression data of the intersection as the intervenable gene target associated with MCP;
[0069] Illustratively, the first GWAS data, i.e., the GWAS data for MCP, is derived from the UK Biobank database;
[0070] Specifically, by integrating the GTEx V8 data set, first, the gene expression data of the whole blood and the gene expression data of the brain tissue were associated with the corresponding genetic variation data in the GWAS data by using the FUSION software tool, and then the gene expression data in the whole blood and brain tissue were analyzed by the whole transcriptome association analysis (TWAS) method, and the P value and Z-score value of the gene expression data of the whole blood and the gene expression data of the brain tissue were calculated, and then the P value of the gene expression data of the whole blood and the gene expression data of the brain tissue was subjected to FDR correction (false discovery rate correction, using the Benjamini-Hochberg method), and the corrected P value was less than 0.05, which was confirmed as the final significant result, that is, the first candidate gene expression data related to MCP;
[0071] It should be noted that the smaller the P value, the higher the association between the gene and MCP;
[0072] It should be noted that the present application requires the use of the effect value direction of the first effect value (Z-score value) but does not require the specific numerical value of the Z-score value. The first effect value direction means that when the Z-score value is positive, the corresponding first effect value direction is the positive direction, and when the Z-score value is negative, the corresponding first effect value direction is the negative direction.
[0073] See also Figure 2-Figure 3 ,in, Figure 2 This is the whole blood result of TWAS. Figure 3This is the brain tissue result of TWAS. The dotted line is the threshold of the FDR correction value. Only when the corrected P value of the candidate gene data is less than the FDR correction threshold will it be considered statistically significant. Figure 2 Above and Figure 3 The figure above shows the gene expression data when the effect value direction of the Z-score is positive. Figure 2 The following figure and Figure 3 The figure below shows the gene expression data when the effect value of the Z-score value is in the negative direction. Figure 2 as well as Figure 3 The ordinate is the converted value of the P value, and the abscissa is the position of each chromosome;
[0074] See also Figure 4-Figure 7 Specifically, since false positives may occur when only one method is used, the gene expression data of the whole blood and the gene expression data of the brain tissue are then verified by using the Summary-data-based Mendelian Randomization (SMR) and Heterogeneity in Dependent Instruments (HEIDI) tests through the SMR software tool to obtain the p-SMR value, p-HEIDI value and beta-SMR value of the gene expression data of the whole blood and the brain tissue, and the p-SMR value of each gene expression data is FDR corrected by FDR correction to obtain the candidate gene expression data with a corrected p-SMR value less than 0.05, and then the second candidate gene expression data with a p-HEIDI value greater than 0.01 and the first effect value direction (i.e., the effect value direction of the Z-score value) and the second effect value direction (i.e., the effect value direction of the beta-SMR value) are screened; that is, the direction of the first effect value (Z-score value) of the second candidate gene expression data and the direction of the second effect value (beta-SMR value) are the same positive or negative;
[0075] in, Figure 4 This is the SMR&HEIDI result diagram of whole blood. Figure 5 This is the SMR&HEIDI result diagram of brain tissue, and the dotted line is the threshold of the FDR correction value;
[0076] It should be noted that the present application requires the use of the effect value direction of the second effect value (beta-SMR value) but does not require the specific numerical value of the beta-SMR value. The second effect value direction means that when the beta-SMR value is positive, the corresponding second effect value direction is positive, and when the beta-SMR value is negative, the corresponding second effect value direction is negative.
[0077] It should be noted that the p-SMR value represents the statistical significance of the relationship between the gene and MCP. The HEIDI method was then used to determine whether the effect of the genetic variation site on MCP was mediated by gene expression to exclude the horizontal pleiotropy of genetic variation. If the p-HEIDI value is greater than 0.01, it is considered that the possibility of horizontal pleiotropy is small, indicating that the genetic variation affects MCP through the expression of the gene, that is, the expression of the gene has a causal relationship with MCP.
[0078] Finally, the results obtained by TWAS and SMR&HEIDI, i.e., the first candidate gene expression data and the second candidate gene expression data, were crossed to obtain the intersection part, and the gene expression data of the intersection part was used as the intervenable gene target related to MCP to generate the intervenable gene target set, where: Figure 6 For the crossover results of whole blood, Figure 7 Cross-sectional results for brain tissue.
[0079] In a preferred embodiment, the determining of several intervenable protein targets related to MCP based on the first GWAS data, the gene expression data and the brain protein expression data includes:
[0080] Using the blood protein expression data in the deCODE data set and the brain protein expression data in the NIAGADS data set as exposure data for two-sample Mendelian randomization, and using the first GWAS data as result data for two-sample Mendelian randomization, two-sample Mendelian randomization is performed to obtain the third effect value direction and P value corresponding to the blood protein expression data and the brain protein expression data;
[0081] Performing FDR correction on the P values of the blood protein expression data and the brain protein expression data to obtain MR-positive proteins whose corrected P values are less than an FDR correction threshold;
[0082] The MR-positive proteins are subjected to Bayesian co-localization analysis, and the MR-positive proteins with a posterior probability greater than a preset value are taken as the intervenable protein targets associated with MCP;
[0083] Specifically, the blood protein expression data in the deCODE data set and the brain protein expression data in the NIAGADS data set were used as exposure data for two-sample Mendelian randomization, and the first GWAS data were used as result data for two-sample Mendelian randomization, and a two-sample Mendelian randomization (MR) analysis was performed to obtain the P values and beta-MR values of the blood protein expression data and the brain protein expression data, and then the P values of the blood protein expression data and the brain protein expression data were FDR corrected to obtain MR-positive proteins with a corrected P value less than 0.05;
[0084] It should be noted that two-sample Mendelian randomization analysis is a fixed name for an analysis method. "Two samples" means that the exposure data and outcome data come from different populations. Specifically in the present invention, "exposure data" refers to data such as genes and proteins coming from one population, while "outcome data" refers to data on chronic pain in multiple sites coming from different populations of the same ethnic group.
[0085] Specifically, since MR-positive proteins have been obtained, it is necessary to further analyze these positive proteins by Bayesian co-localization to identify whether there are shared mutation sites between potential protein targets and MCP, that is, whether there is a certain genetic mutation site that changes the expression of a certain protein, thereby causing the generation of the MCP phenotype; thus, the co-localization results are divided by using the Coloc software tool;
[0086] It should be noted that the Coloc posterior probability has the following assumptions: (1) H0: indicates that no genetic variation site was found to be associated with MCP or the expression of the detected protein; (2) H1: indicates that a genetic variation site was found to be associated with protein expression but not with MCP; (3) H2: indicates that a genetic variation site was found to be associated with MCP but not with protein expression; (4) H3: indicates that two genetic variation sites were found to be associated with protein expression and MCP respectively; (5) H4: indicates that a genetic variation site was found to be associated with both protein and MCP;
[0087] Specifically, see Figure 9-10According to the commonly used threshold of the Coloc toolkit, PP.H4>60% is set as the basis for distinguishing whether there is co-localization between protein and MCP. PP.H4>60% means that there is a common genetic variation site between protein and MCP. Therefore, MR-positive proteins with a posterior probability greater than 0.6 are confirmed as co-localization positive, that is, MR-positive proteins with a posterior probability greater than 0.6 are used as intervenable protein target proteins related to MCP. It is believed that the intervenable protein target proteins share pathogenic sites with MCP, and an intervenable protein target set is generated;
[0088] It should be noted that the shared pathogenicity site, i.e., shared genetic variant, is also called single nucleotide polymorphism. This site is a genetic variation site that affects both the level of this protein and the incidence of MCP. Therefore, it is called a shared genetic mutation and is often used in genotyping to determine that the incidence of a certain genotype is higher. The protein target determined through this process is less likely to be affected by horizontal pleiotropy and linkage disequilibrium, and is a reliable potential protein target for intervention;
[0089] Schematically, the intersection of the intervenable gene target set and the intervenable protein target set is determined, and each target in the determined intersection is used as a potential therapeutic target for MCP;
[0090] Specifically, after obtaining the intervenable gene target set and the intervenable protein target set, the intersection of the intervenable gene target set and the intervenable protein target set is taken, and each target in the determined intersection is used as a potential therapeutic target for MCP.
[0091] See also Figure 8 ,In a preferred embodiment, the system for determining potential therapeutic targets for multi-site chronic pain further includes: a cell analysis module;
[0092] The cell analysis module includes a sequencing data acquisition unit, a key cell type analysis unit, and a cell process analysis unit;
[0093] The sequencing data acquisition unit is used to acquire single-cell RNA sequencing data;
[0094] The key cell type unit is used to analyze and obtain key cell types related to the potential therapeutic target of MCP according to the sc-linker analysis method, the potential therapeutic target of MCP and the single-cell RNA sequencing data;
[0095] The cell process analysis unit is used to analyze and obtain the cell process related to the potential therapeutic target of MCP according to the sc-linker analysis method, the potential therapeutic target of MCP and the single cell RNA sequencing data;
[0096] Schematically, single-cell RNA sequencing data were obtained and sc-linker analysis was used to identify key cell types associated with the potential therapeutic targets of the MCP;
[0097] Specifically, the analysis showed that blood LANCL1 and KLC1 were potential therapeutic targets. Further cell type analysis of these two potential targets revealed that the LANCL1 target was mainly associated with B lymphocytes in the blood, GABAergic neurons, LAMP5+ neurons, VIP+ neurons, L5 / 6NP neurons, L5 ET neurons, and astrocytes in the brain tissue; the KLC1 target was mainly associated with megakaryocytes in the blood, GABAergic neurons, LAMP5+ neurons, PVABL1+ neurons, glutamatergic neurons, IT neurons, L4IT neurons, L5 / 6NP neurons, L5 ET neurons, and L6 CT neurons in the brain tissue;
[0098] Specifically, see Fig.11 ,in, Fig.11 This is the cell type result diagram. Fig.11 (A) is the whole blood result, Fig.11 (B) is the result of brain tissue;
[0099] Schematically, single-cell RNA sequencing data were obtained and sc-linker analysis was used to identify cellular processes associated with the potential therapeutic targets of the MCP;
[0100] Specifically, through sc-linker analysis, it was found that LANCL1 was mainly associated with ribosome processes in the blood and mainly associated with electron transfer processes in brain tissue; KLC1 was found to be related to ribosome processes in the blood and mainly associated with axon guidance processes in brain tissue;
[0101] Specifically, see Fig.12 , a schematic diagram of the relevant cellular processes, Fig.12 (A) is the whole blood result, Fig.12 (B) Results of brain tissue.
[0102] See also Fig.13 ,In a preferred embodiment, the system for determining potential therapeutic targets for chronic pain in multiple sites further comprises: an MCP potential therapeutic target action analysis module;
[0103] The MCP potential therapeutic target analysis module is used to obtain the second GWAS data; according to the plurality of intervenable protein targets and the second GWAS data, obtain a plurality of associated diseases other than MCP for each intervenable protein target and a corresponding fourth effect value direction;
[0104] According to the third effect value direction and the fourth effect value direction of each of the intervenable protein targets, determining whether the intervenable protein target has side effects on the plurality of related diseases;
[0105] Determining whether the intervenable protein target is an additional indication for the plurality of related diseases according to the third effect value direction and the fourth effect value direction of each intervenable protein target;
[0106] Illustratively, the second GWAS data is GWAS data in the FinnGen database (R8) that is not related to MCP;
[0107] Schematically, in order to understand the role of the potential therapeutic target of MCP in other diseases and evaluate the safety and versatility of the potential therapeutic target of MCP, GWAS data unrelated to MCP in the FinnGen database (R8) were used to analyze and evaluate several associated diseases other than MCP for each intervenable protein target and the corresponding fourth effect value by using a two-sample Mendelian randomization analysis method, i.e., MR-PheWAS analysis;
[0108] Specifically, for a certain associated disease of each intervenable protein target, it is determined whether the direction of the fourth effect value of the associated disease is consistent with the direction of the beta-MR value of the intervenable protein target. When the direction of the fourth effect value obtained according to the MR result is inconsistent with the direction of the third effect value, that is, the direction of the fourth effect value is negatively correlated with the direction of the third effect value, then it is determined that the intervenable protein target has a side effect on the associated disease corresponding to the fourth effect value. When the direction of the fourth effect value obtained according to the MR result is consistent with the direction of the third effect value, it means that the direction of the fourth effect value is positively correlated with the third effect value, then it is determined that the associated disease corresponding to the current fourth effect value is an additional indication of the intervenable protein target;
[0109] It should be noted that after obtaining the third effect value (beta-MR effect value), the direction of the beta-MR effect value is needed instead of the specific numerical value of the beta-MR value. The third effect value direction means that when the beta-MR value is positive, the corresponding third effect value direction is the positive direction, and when the beta-MR value is negative, the corresponding third effect value direction is the negative direction.
[0110] See also Fig.14 ,In a preferred embodiment, the system for identifying potential therapeutic targets for multi-site chronic pain further includes: a protein network construction and analysis module;
[0111] The protein network construction and analysis module includes a protein network construction unit and a protein network analysis unit;
[0112] The protein network construction unit is used to input the intervenable protein target into a tool for constructing a protein interaction network, so that the tool constructs a network according to the input data;
[0113] The protein network analysis unit is used to analyze the pathways and biological processes involved in the intervenable protein target, and the proteins interacting with the intervenable protein target, based on the constructed network;
[0114] Schematically, the intervenable protein target is input into GeneMANIA, so that GeneMANIA constructs a protein interaction network and analyzes the pathways and biological processes involved in the intervenable protein target, as well as the proteins interacting with the intervenable protein target;
[0115] Specifically, see Fig.15 The pathways and biological processes involved in the interventional protein targets include synaptic protein localization, cell junction protein localization, axonal transport, presynaptic protein localization, axon-dendrite transport, and cytoskeleton-dependent intracellular transport. Fig.13 outer ring protein.
[0116] The above is a preferred embodiment of the present invention. It should be pointed out that a person skilled in the art can make several improvements and modifications without departing from the principle of the present invention. These improvements and modifications are also considered to be within the scope of protection of the present invention.
Claims
1. A system for determining potential therapeutic targets for chronic pain in multiple sites, characterized in that: include: Data acquisition module, interventionable gene target confirmation module, interventionable protein target confirmation module, MCP potential therapeutic target confirmation module, and protein network construction and analysis module; The data acquisition module is used to acquire the first GWAS data, the gene expression data of whole blood and the gene expression data of brain tissue in the GTEx V8 data set, the blood protein expression data in the deCODE data set, and the brain protein expression data in the NIAGADS data set; wherein the first GWAS data is the GWAS data related to MCP; The intervenable gene target confirmation module is used to perform whole transcriptome association analysis based on the gene expression data of the whole blood, the gene expression data of the brain tissue, and the corresponding genetic variation data in the first GWAS data to obtain the P value and the first effect value direction of the gene expression data of the whole blood and the gene expression data of the brain tissue; Performing FDR correction on the P values of the whole blood gene expression data and the brain tissue gene expression data to obtain first candidate gene expression data whose corrected P value is less than a preset FDR correction threshold; Performing SMR&HEIDI analysis on the gene expression data of the whole blood and the gene expression data of the brain tissue to obtain a p-SMR value, a p-HEIDI value and a second effect value direction corresponding to each gene expression data of the whole blood and each gene expression data of the brain tissue; Performing FDR correction on the p-SMR value of each gene expression data to obtain candidate gene expression data whose corrected p-SMR value is less than a preset FDR correction threshold, screening out second candidate gene expression data whose p-HEIDI value is greater than a preset value and whose first effect value direction is consistent with the second effect value direction from among the candidate gene expression data whose corrected p-SMR value is less than the preset FDR correction threshold; Taking the intersection of the first candidate gene expression data and the second candidate gene expression data, taking the gene expression data of the intersection as the intervenable gene target related to MCP, and generating an intervenable gene target set; The intervenable protein target confirmation module is used to determine several intervenable protein targets related to MCP according to the first GWAS data, the blood protein expression data and the brain protein expression data, and generate an intervenable protein target set; wherein, the determining several intervenable protein targets related to MCP according to the first GWAS data, the blood protein expression data and the brain protein expression data includes: Using the blood protein expression data in the deCODE data set and the brain protein expression data in the NIAGADS data set as exposure data for two-sample Mendelian randomization, and using the first GWAS data as result data for two-sample Mendelian randomization, two-sample Mendelian randomization is performed to obtain the third effect value direction and P value corresponding to the blood protein expression data and the brain protein expression data; Performing FDR correction on the P values of the blood protein expression data and the brain protein expression data to obtain MR-positive proteins whose corrected P values are less than an FDR correction threshold; The MR-positive proteins are subjected to Bayesian co-localization analysis, and the MR-positive proteins with a posterior probability greater than a preset value are taken as the intervenable protein targets associated with MCP; The MCP potential therapeutic target confirmation module is used to determine the intersection of the intervenable gene target set and the intervenable protein target set, and use each target in the determined intersection as a potential therapeutic target for MCP; The protein network construction and analysis module includes a protein network construction unit and a protein network analysis unit; The protein network construction unit is used to input the intervenable protein target into a tool for constructing a protein interaction network, so that the tool constructs a network according to the input data; The protein network analysis unit is used to analyze the pathways and biological processes involved in the intervenable protein target and the proteins interacting with the intervenable protein target based on the constructed network; wherein the involved pathways and biological processes include: synaptic protein localization, cell-connected protein localization, axonal transport, presynaptic protein localization, axon-dendrite transport and cytoskeleton-dependent intracellular transport.
2. The system for determining potential therapeutic targets for chronic pain in multiple sites according to claim 1, characterized in that: Also includes: cell analysis module; The cell analysis module includes a sequencing data acquisition unit, a key cell type analysis unit, and a cell process analysis unit; The sequencing data acquisition unit is used to acquire single-cell RNA sequencing data; The key cell type analysis unit is used to analyze and obtain key cell types related to the potential therapeutic target of MCP according to the sc-linker analysis method, the potential therapeutic target of MCP and the single-cell RNA sequencing data; The cell process analysis unit is used to analyze and obtain the cell process related to the potential therapeutic target of MCP according to the sc-linker analysis method, the potential therapeutic target of MCP and the single-cell RNA sequencing data.
3. The system for determining potential therapeutic targets for chronic pain in multiple sites as claimed in claim 1, characterized in that: Also includes: MCP potential therapeutic target action analysis module; The MCP potential therapeutic target effect analysis module is used to obtain the second GWAS data, and obtain a number of associated diseases other than MCP for each intervenable protein target and a corresponding fourth effect value direction based on the number of intervenable protein targets and the second GWAS data; According to the third effect value direction and the fourth effect value direction of each of the intervenable protein targets, determining whether the intervenable protein target has side effects on the plurality of related diseases; According to the third effect value direction and the fourth effect value direction of each of the intervenable protein targets, it is determined whether the intervenable protein target is an additional indication for the plurality of related diseases.
